beraprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
prostaglandins 343 88430-50-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • procylin
  • beraprost sodium
  • beraprost
stable prostacyclin analog; structure given in first source
  • Molecular weight: 398.50
  • Formula: C24H30O5
  • CLOGP: 1.89
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 86.99
  • ALOGS: -4.60
  • ROTB: 9

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 19 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.01 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.671 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 4.688 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 47.534 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 5.129 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 10.490 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 14.980 % High 1
herg hERG pIC50 4.403 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 3.273 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.221 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 6.730 % High 1
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SYK,TEK,TGFBR1 23
kinase-selectivity-class GRK2,MAP2K6 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 7.980 High 1
mh-clint Mouse hepatocyte intrinsic clearance 26.242 High 1
mppb Mouse plasma protein binding (% unbound) 13.170 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 13.062 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 13.980 % High 1
rh-clint Rat hepatocyte intrinsic clearance 19.679 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 82.120 % High 1
rppb Rat plasma protein binding (% unbound) 6.830 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 859.014 uM High 1

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1992 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pulmonary hypertension 136.63 31.83 53 3220 42470 90582704
Cardiac failure 132.90 31.83 69 3204 109427 90515747
Right ventricular failure 131.31 31.83 42 3231 19163 90606011
Concomitant disease aggravated 107.54 31.83 32 3241 11486 90613688
Hepatic function abnormal 85.73 31.83 39 3234 46249 90578925
Brain natriuretic peptide increased 84.57 31.83 23 3250 5982 90619192
Transfusion 82.73 31.83 29 3244 17459 90607715
Anaemia 78.56 31.83 79 3194 352723 90272451
Upper respiratory tract inflammation 71.06 31.83 17 3256 2655 90622519
Platelet count decreased 68.61 31.83 49 3224 136920 90488254
Gamma-glutamyltransferase increased 57.95 31.83 28 3245 37924 90587250
Blood pressure decreased 57.48 31.83 35 3238 74860 90550314
Iron deficiency anaemia 56.98 31.83 24 3249 23638 90601536
Pulmonary arterial hypertension 54.64 31.83 24 3249 26163 90599011
Interstitial lung disease 54.30 31.83 34 3239 76371 90548803
Aspartate aminotransferase increased 40.73 31.83 32 3241 102905 90522269
Haematocrit decreased 38.50 31.83 22 3251 41810 90583364
Renal impairment 37.93 31.83 31 3242 105390 90519784
Haemoglobin decreased 37.25 31.83 37 3236 161919 90463255
Pulmonary arterial pressure increased 37.05 31.83 11 3262 3905 90621269
Red blood cell count decreased 36.41 31.83 22 3251 46329 90578845
Alanine aminotransferase increased 32.84 31.83 30 3243 118308 90506866

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Right ventricular failure 99.15 31.77 28 1332 9527 42610448
Concomitant disease aggravated 76.06 31.77 21 1339 6565 42613410
Brain natriuretic peptide increased 61.94 31.77 18 1342 6752 42613223
Cardiac failure 59.92 31.77 39 1321 106817 42513158
Pulmonary hypertension 56.61 31.77 23 1337 23546 42596429
Pulmonary arterial hypertension 35.34 31.77 13 1347 10174 42609801

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Right ventricular failure 219.19 27.75 70 4834 25884 110558511
Pulmonary hypertension 181.20 27.75 74 4830 55146 110529249
Concomitant disease aggravated 175.43 27.75 53 4851 16311 110568084
Cardiac failure 167.94 27.75 104 4800 187522 110396873
Brain natriuretic peptide increased 140.58 27.75 41 4863 11168 110573227
Hepatic function abnormal 96.59 27.75 56 4848 89239 110495156
Anaemia 84.38 27.75 112 4792 546974 110037421
Transfusion 83.00 27.75 34 4870 25438 110558957
Upper respiratory tract inflammation 82.34 27.75 22 4882 4349 110580046
Pulmonary arterial hypertension 81.34 27.75 36 4868 32532 110551863
Platelet count decreased 79.19 27.75 72 4832 230371 110354024
Iron deficiency anaemia 63.44 27.75 30 4874 31529 110552866
Interstitial lung disease 58.83 27.75 49 4855 139285 110445110
Gamma-glutamyltransferase increased 52.19 27.75 33 4871 61276 110523119
Blood pressure decreased 51.77 27.75 42 4862 115049 110469346
Aspartate aminotransferase increased 47.25 27.75 46 4858 159890 110424505
Alanine aminotransferase increased 40.18 27.75 45 4859 183728 110400667
Haemoglobin decreased 38.29 27.75 51 4853 248676 110335719
Red blood cell count decreased 36.01 27.75 27 4877 65896 110518499
Pulmonary arterial pressure increased 35.84 27.75 12 4892 5115 110579280
Haematocrit decreased 33.73 27.75 26 4878 66091 110518304
Blood urea increased 33.38 27.75 24 4880 54933 110529462
Fatigue 32.86 27.75 7 4897 1215951 109368444
Renal impairment 31.09 27.75 40 4864 188405 110395990
Pleural effusion 29.76 27.75 38 4866 177671 110406724
Pulmonary congestion 29.72 27.75 18 4886 30948 110553447
Ascites 27.96 27.75 27 4877 92781 110491614

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AC19 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Platelet aggregation inhibitors excl. heparin
MeSH PA D002317 Cardiovascular Agents
MeSH PA D006401 Hematologic Agents
MeSH PA D010975 Platelet Aggregation Inhibitors
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:50427 platelet aggregation inhibitor
CHEBI has role CHEBI:66900 prostaglandin receptor agonist
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:231911 renoprotective agent
CHEBI has role CHEBI:50249 anticoagulant

Related Drugs by ATC class:

B01AC Platelet aggregation inhibitors excl. heparin 24 drugs
abciximabacetylsalicylic acidaloxiprincangrelorcarbasalate calciumcilostazolclopidogrelcloricromendipyridamoleditazoleepoprostenoleptifibatide show all 24 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pulmonary arterial hypertension indication 11399002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.76 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prostacyclin receptor GPCR AGONIST IC50 8.37 WOMBAT-PK DRUG LABEL
Prostaglandin E2 receptor EP3 subtype GPCR AGONIST Ki 6.17 IUPHAR
Prostaglandin E2 receptor EP4 subtype GPCR AGONIST Ki 5.14 IUPHAR
Prostacyclin receptor GPCR AGONIST Ki 7.80 IUPHAR
Prostacyclin receptor GPCR AGONIST Ki 7.72 IUPHAR

External reference:

IDSource
D01551 KEGG_DRUG
88475-69-8 SECONDARY_CAS_RN
C0053336 UMLSCUI
CHEBI:135633 CHEBI
CHEMBL1207745 ChEMBL_ID
CHEMBL435883 ChEMBL_ID
DB05229 DRUGBANK_ID
C048081 MESH_SUPPLEMENTAL_RECORD_UI
6917951 PUBCHEM_CID
1967 IUPHAR_LIGAND_ID
6261 INN_ID
35E3NJJ4O6 UNII
010867 NDDF
010868 NDDF
35E3NJJ4O6 INXIGHT DRUGS

Pharmaceutical products:

None